Wellness
Cellares raises $255M as it prepares to manufacture cell therapies
Cellares, which is known for producing the technology used in cell therapy manufacturing, has raised $255 million in a Series C as it aims to build out…
Cellares, which is known for producing the technology used in cell therapy manufacturing, has raised $255 million in a Series C as it aims to build out its own manufacturing business.
Fabian GerlinghausThe company’s thinking is that contract manufacturers are not currently able to meet global demand, which has created a need for more CDMOs with the technical know-how to manufacture cell therapies, Cellares CEO Fabian Gerlinghaus told Endpoints News.
“The demand for cell therapies is not met by the existing use of CDMOs, and we thought we could do better than conventional CDMOs,” he said.
Cellares said it now plans to build its commercial-scale factory in a 118,000-square-foot building in Bridgewater, NJ, that is set to open in the second half of 2024. It will employ 350 workers.
The plant will have 50 so-called Cell Shuttles, a portable piece of equipment about the size of a truck that acts as a mobile factory that Cellares has been developing since 2019. The shuttle, which can produce 16 personalized cell therapies at a time, uses robotics and software to automate cell therapy manufacturing.
Cellares currently has a 57,000-square-foot location in South San Francisco, and it plans to begin producing cell therapies for clinical trials there next year. The company also has plans to expand globally, with a site expected to come online in Europe in 2025 and another in Asia after that.
The round, which Cellares announced Wednesday, was funded by Koch Disruptive Technologies and Bristol Myers Squibb, among others.
Lion’s Mane Mushroom: History, Benefits, and Adaptogen Properties
Explore the intriguing world of Lion’s Mane Mushroom in our comprehensive guide. Dive into its unique properties, historical significance, and myriad health…
AI can already diagnose depression better than a doctor and tell you which treatment is best
Artificial intelligence (AI) shows great promise in revolutionizing the diagnosis and treatment of depression, offering more accurate diagnoses and predicting…
Reasons You should Get this: Neptune Wellness Solutions Inc (NASDAQ:NEPT), WeTrade Group Inc. (NASDAQ:WETG)
NEPT has seen its SMA50 which is now -9.28%. In looking the SMA 200 we see that the stock has seen a -92.25%. WETG has seen its SMA50 which is …
The…
